Literature DB >> 28244992

Overcoming cellular barriers for RNA therapeutics.

Steven F Dowdy1.   

Abstract

RNA-based therapeutics, such as small-interfering (siRNAs), microRNAs (miRNAs), antisense oligonucleotides (ASOs), aptamers, synthetic mRNAs and CRISPR-Cas9, have great potential to target a large part of the currently undruggable genes and gene products and to generate entirely new therapeutic paradigms in disease, ranging from cancer to pandemic influenza to Alzheimer's disease. However, for these RNA modalities to reach their full potential, they first need to overcome a billion years of evolutionary defenses that have kept RNAs on the outside of cells from invading the inside of cells. Overcoming the lipid bilayer to deliver RNA into cells has remained the major problem to solve for widespread development of RNA therapeutics, but recent chemistry advances have begun to penetrate this evolutionary armor.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28244992     DOI: 10.1038/nbt.3802

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  216 in total

Review 1.  Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug.

Authors:  Alexandre J Debacker; Jon Voutila; Matthew Catley; David Blakey; Nagy Habib
Journal:  Mol Ther       Date:  2020-06-17       Impact factor: 11.454

2.  Quantitative measurement of cytosolic penetration using the chloroalkane penetration assay.

Authors:  Kirsten Deprey; Joshua A Kritzer
Journal:  Methods Enzymol       Date:  2020-04-20       Impact factor: 1.600

3.  Gal8 Visualization of Endosome Disruption Predicts Carrier-Mediated Biologic Drug Intracellular Bioavailability.

Authors:  Kameron V Kilchrist; Somtochukwu C Dimobi; Meredith A Jackson; Brian C Evans; Thomas A Werfel; Eric A Dailing; Sean K Bedingfield; Isom B Kelly; Craig L Duvall
Journal:  ACS Nano       Date:  2019-01-18       Impact factor: 15.881

4.  Design and assessment of engineered CRISPR-Cpf1 and its use for genome editing.

Authors:  Bin Li; Chunxi Zeng; Yizhou Dong
Journal:  Nat Protoc       Date:  2018-04-05       Impact factor: 13.491

Review 5.  GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics.

Authors:  Aaron D Springer; Steven F Dowdy
Journal:  Nucleic Acid Ther       Date:  2018-05-24       Impact factor: 5.486

6.  High-Throughput Analysis Reveals Rules for Target RNA Binding and Cleavage by AGO2.

Authors:  Winston R Becker; Benjamin Ober-Reynolds; Karina Jouravleva; Samson M Jolly; Phillip D Zamore; William J Greenleaf
Journal:  Mol Cell       Date:  2019-07-16       Impact factor: 17.970

Review 7.  Epigenetics and epigenomics in diabetic kidney disease and metabolic memory.

Authors:  Mitsuo Kato; Rama Natarajan
Journal:  Nat Rev Nephrol       Date:  2019-06       Impact factor: 28.314

Review 8.  Aptamers as Therapeutic Agents: Has the Initial Euphoria Subsided?

Authors:  S K Haßel; G Mayer
Journal:  Mol Diagn Ther       Date:  2019-06       Impact factor: 4.074

9.  Strategies for Efficient Genome Editing Using CRISPR-Cas9.

Authors:  Behnom Farboud; Aaron F Severson; Barbara J Meyer
Journal:  Genetics       Date:  2018-11-30       Impact factor: 4.562

Review 10.  Targeting RNA in mammalian systems with small molecules.

Authors:  Anita Donlic; Amanda E Hargrove
Journal:  Wiley Interdiscip Rev RNA       Date:  2018-05-03       Impact factor: 9.957

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.